Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trialnews2026-04-27T11:30:28+00:00April 27th, 2026|Endpoints News|
Intellia’s in vivo CRISPR therapy first to succeed in Phase 3news2026-04-27T11:01:29+00:00April 27th, 2026|Endpoints News|
Veradermics wins at growing hair with oral Rogaine in first key test as a public companynews2026-04-27T11:00:29+00:00April 27th, 2026|Endpoints News|
FDA unveils three psychedelic-focused commissioner vouchersnews2026-04-24T17:26:49+00:00April 24th, 2026|Endpoints News|
Substance use disorder biotech Tempero to close after earlier ‘serious’ safety eventnews2026-04-23T18:13:36+00:00April 23rd, 2026|Endpoints News|
Sanofi defends Garijo appointment, says it is ‘fully committed’ to immunologynews2026-04-23T09:00:47+00:00April 23rd, 2026|Endpoints News|
Sanofi’s new CEO faces a reckoning on immunology-focused R&D strategynews2026-04-22T15:25:28+00:00April 22nd, 2026|Endpoints News|
Rigel loses Lilly alliance in pharma industry’s latest RIPK exitnews2026-04-22T14:41:53+00:00April 22nd, 2026|Endpoints News|
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoringnews2026-04-21T23:15:15+00:00April 21st, 2026|Endpoints News|
Merck’s Welireg combo fails in first-line kidney cancernews2026-04-21T18:01:54+00:00April 21st, 2026|Endpoints News|
